SCHEMBL4089149

SCHEMBL4089149

O=C(O)C(=O)Nc1nc(-c2ccc(Cl)cc2)cs1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.72
KMT2A Q03164 6/20 0.67
MEN1 O00255 5/20 0.67
GSTO1 P78417 1/20 0.67
ALDH1A1 P00352 2/20 0.64
MAPT P10636 5/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
RAB9A P51151 3/20 0.59
NPC1 O15118 3/20 0.59
LMNA P02545 2/20 0.58
ALOX12 P18054 2/20 0.58
MAPK1 P28482 1/20 0.58
HTT P42858 1/20 0.58
ALOX5 P09917 1/20 0.57
ROCK2 O75116 1/20 0.55
ROCK1 Q13464 1/20 0.55
USP2 O75604 1/20 0.55
ALOX15 P16050 1/20 0.55
HSD17B10 Q99714 1/20 0.55
SIRT5 Q9NXA8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10924496 0.92 ABL1 (0.78) ABL1KMT2AMEN1GSTO1ALDH1A1
SCHEMBL11138234 0.87 AMY1A (0.59) ABL1KMT2AMEN1GSTO1ALDH1A1
SCHEMBL11136424 0.86 MAPT (0.68) KMT2AMEN1GSTO1ALDH1A1MAPT
SCHEMBL10808572 0.86 MEN1 (0.82) ABL1KMT2AMEN1GSTO1ALDH1A1
SCHEMBL11478316 0.85 LMNA (0.67) KMT2AMEN1ALDH1A1MAPTSMN1; SMN2
SCHEMBL9893009 0.84 ABL1 (1.00) ABL1KMT2AMEN1GSTO1ALDH1A1
SCHEMBL6638228 0.84 ABL1 (0.74) ABL1KMT2AMEN1GSTO1ALDH1A1
SCHEMBL11475450 0.82 MAPT (0.54) ABL1KMT2AMEN1GSTO1ALDH1A1
SCHEMBL11137982 0.82 MEN1 (0.70) KMT2AMEN1GSTO1ALDH1A1MAPT
SCHEMBL23604714 0.81 ABL1 (0.74) ABL1KMT2AMEN1GSTO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7618990-B2 4-[2-(4,4-Dimethyl-2-thioxo-1,3-oxazolidin-3-yl)-1,3-thiazol-4-yl]benzonitrile; progesterone receptor (PR); contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, hormone replacement therapy WYETH (US) 2009-11-17 US disclosed
EP-2054410-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS Wyeth (US) 2009-05-06 EP disclosed
US-20080045556-A1 Oxazolidone derivatives as PR modulators WYETH (US) 2008-02-21 US disclosed
WO-2008021331-A2 OXAZOLIDONE DERIVATIVES AS PR MODULATORS WYETH (US) 2008-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045556-A1 Oxazolidone derivatives as PR modulators MC2R, NPY1R, PRLHR ABL1 4372/4885KMT2A 667/4885MEN1 699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.